Related Experiment Videos
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset
1University Department of Neurology, Institute of Psychiatry, Denmark Hill, London, England.
Abstract:
Administration of MPTP (1-4 mg/kg ip daily for 5-7 days) to common marmosets induced persistent parkinsonian motor deficits. The subcutaneous administration of (+)-PHNO [(+)-4-propyl-9-hydroxynaphthoxazine; 1-4 micrograms/kg] caused a dose-dependent reversal of the akinesia and incoordination of movement. Similarly, oral administration of (+)-PHNO (5-20 micrograms/kg) caused an equivalent reversal of the motor abnormalities. No dyskinetic phenomena were induced by (+)-PHNO on oral or subcutaneous administration. Oral or subcutaneous administration of (+)-PHNO to normal control marmosets also increased the usual repetoire of motor behaviour, but this was not as marked as in MPTP-treated animals. (+)-PHNO is a potent dopamine agonist drug of potential use in the treatment of Parkinson's disease.
Insights
MPTP administration induced parkinsonian deficits in marmosets. (+)-PHNO, a dopamine agonist, reversed these motor deficits effectively and safely, showing potential for Parkinson's disease treatment.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease is a neurodegenerative disorder characterized by motor deficits.
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to model Parkinson's disease in primates.
- Dopamine agonists are a key therapeutic strategy for Parkinson's disease.
Purpose of the Study:
- To evaluate the efficacy of (+)-PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] in reversing MPTP-induced parkinsonian motor deficits in common marmosets.
- To assess the safety profile of (+)-PHNO, specifically looking for dyskinetic side effects.
Main Methods:
- Common marmosets were administered MPTP to induce persistent parkinsonian motor deficits.
- (+)-PHNO was administered subcutaneously and orally at various doses.
- Motor behavior was assessed to quantify the reversal of akinesia and incoordination.
Main Results:
- Subcutaneous and oral administration of (+)-PHNO dose-dependently reversed MPTP-induced akinesia and incoordination.
- No dyskinetic phenomena were observed with (+)-PHNO administration in MPTP-treated or control marmosets.
- (+)-PHNO enhanced motor behavior in normal marmosets, though less pronounced than in MPTP-treated animals.
Conclusions:
- (+)-PHNO is a potent dopamine agonist.
- It effectively reverses parkinsonian motor deficits in a primate model.
- (+)-PHNO demonstrates potential as a therapeutic agent for Parkinson's disease due to its efficacy and favorable safety profile.